Muna amfani da ilimin kimiya na yanke hukunci don ƙirƙirar sabbin hanyoyin kwantar da hankali waɗanda za su inganta rayuwar waɗanda ke fama da cutar kansa, ciwo mai saurin jurewa da COVID-19.
Cancer yana da bambancin kwayoyin halitta, yana daidaitawa sosai, yana canzawa koyaushe kuma kusan ba a iya gani ga tsarin rigakafi. Hanyarmu game da maganin ciwon daji ya dogara ne akan imani cewa marasa lafiya zasu buƙaci tsarin multimodal, multipronged - yin niyya guda ɗaya ko bambance-bambancen saiti na salon salula da kuma kai hari ga waɗanda ke kan gaba da yawa - lokaci guda ko a jere, akai-akai kuma ba tare da ɓata lokaci ba.
Hanyarmu don yaƙar cutar kansa ta yiwu ne ta hanyar babban fayil ɗin immuno-oncology (“IO”), wanda ya ƙunshi ɗimbin sabbin abubuwa da kadarori, kamar babban ɗakin karatu na rigakafin mutum (“G-MAB™”) wanda zai iya. a yi amfani da su da kansu ko kuma a haɗa su cikin hanyoyin magance cutar kansa ciki har da:
Waɗannan kaddarorin suna cike da sabuwar na'ura mai niyya ta lymphatic (Sofusa®) da aka tsara don isar da ƙwayoyin rigakafi a cikin tsarin lymphatic, inda aka horar da ƙwayoyin rigakafi don yaƙar ciwon daji.
Mun ƙirƙira ƙwayoyin rigakafi na ɗan adam akan manufa da yawa masu mahimmanci a cikin maganin cutar kansa, gami da PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, da sauran maƙasudi da yawa, waɗanda suke a matakai daban-daban na haɓakawa. Shirye-shiryen mu na CAR-T sun haɗa da matakin asibiti CD38 CAR T. Hanyoyin warkewa waɗanda ke haɗa hanyoyin suna cikin ƙimar ƙimar matakin farko don yawancin myeloma, ciwon huhu, da sauran manya da cututtukan daji na yara.
- CAR T (Chimeric Antigen Receptor - T Cells) far wanda ke canza ƙwayoyin T-cell na majiyyaci don kashe ƙwayar su
- DAR T (Dimeric Antigen Receptor – T Cells) far wanda ke canza ƙwayoyin T-cell masu ba da lafiya don su zama masu amsa ga duk wani ƙari na majiyyaci, yana ba da izinin “daga kan shiryayye” maganin ciwon mara lafiya.
- Antibody-Drug Conjugates ("ADCs"), da
- Shirye-shiryen Cutar Oncolytic (Seprehvir™, Seprehvec™)
“Tambarin mu na musamman na kadarorin dandamali na IO ba shi da kima a cikin masana'antar. Ya haɗa da masu hanawa na rigakafi, bispecific antibodies, antibody-drug conjugates (ADCs) da kuma chimeric antigen receptor (CAR) da dimeric antigen receptor (DAR) hanyoyin kwantar da hankulan salula, kuma kwanan nan mun ƙara ƙwayoyin cuta na oncolytic (Seprehvir ™, Seprehvec). ™). Kowane kadari a ɗaiɗaiku yana nuna babban alkawari; tare muna jin suna da yuwuwar shawo kan ƙalubalen ƙalubalen ciwon daji”
– Dr. Henry Ji, Shugaba
Ƙaddamar da mu don inganta rayuwar marasa lafiya tare da abin da ake tunani a halin yanzu a matsayin ciwo mai raɗaɗi kuma an nuna shi ta hanyar ƙoƙarin da muke yi don bunkasa ƙananan ƙwayoyin cuta na farko (TRPV1 agonist) ba tare da opioid ƙananan ƙwayoyin cuta ba, Resiniferatoxin ("RTX").
Resiniferatoxin yana da damar da za a canza tsarin tsarin kula da ciwo a cikin nau'i-nau'i daban-daban, saboda tasiri mai karfi da kuma dogon lokaci tare da gwamnati guda ɗaya amma kuma saboda amfanin bayanan da ba na opioid ba.
RTX tana kammala gwaje-gwaje masu mahimmanci a cikin alamun ɗan adam kamar osteoarthritis da ƙarshen ciwon daji na rayuwa, tare da mahimman karatun rajista da aka tsara don fara rabin na biyu na 2020.
Hakanan RTX yana cikin gwaje-gwaje masu mahimmanci don aikace-aikace a cikin karnukan abokan hulɗa tare da wahalar sarrafa ciwon gwiwar gwiwar arthritic. Kamar yadda dabbobin gida ke cikin dangi, tsarinmu don haɓaka sabbin hanyoyin magance ciwo yana nufin ya haɗa da sauran nau'ikan da muke ƙauna!